Levothyroxine compositions having unique triiodothyronine Cmax properties
OwnerG. Andrew Franz, Elaine A. Strauss +2inventors
InventorsG. Andrew Franz, Elaine A. Strauss, Philip A. DiMenna, Rocco L. Gemma
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Claims4
An immediate release pharmaceutical composition comprising a levothyroxine salt, wherein the composition exhibits a triiodothyronine (T3) plasma Cmax of between from about 0.1 ng/ml to about 10 ng/ml as determined by the standard Cmax test.
Dependencies are inferred from the claim text.